A standing ovation for RevMed, and caution for Akeso
The American Society of Clinical Oncology (ASCO) annual meeting always brings together the brightest minds in the field of oncology. Oncologists are known for their discerning applause, saving their standing ovations for truly remarkable presentations. Today, the crowd erupted in cheers and applause for a groundbreaking talk that left everyone in awe.
While the plenary session may have concluded, ASCO is far from over. Stay tuned for our final newsletter installment tomorrow, and don’t forget to check out our virtual recap on Wednesday.
For exclusive coverage of ASCO and other biotech news, consider subscribing to STAT+. Our team of expert writers, including Adam Feuerstein, Matthew Herper, Katherine MacPhail, and Angus Chen, provide in-depth analysis and insights into the latest developments in the field of oncology and beyond.
Adam Feuerstein, a senior writer and biotech columnist, delves into the intersection of drug development, business, and biotechnology. He is also the co-host of the popular biotech podcast, The Readout Loud, and the author of the newsletter, Adam’s Biotech Scorecard.
Matthew Herper focuses on medical innovation and the challenges and triumphs that come with it. As a senior writer and Editorial Director of Events, he brings a unique perspective to the ever-evolving world of medicine.
Katherine MacPhail, a reporter and editorial events programmer, provides insightful coverage of live journalism events and keeps readers informed about the latest trends in the industry.
Angus Chen reports on basic research, clinical science, and drug development that have the potential to revolutionize patient care and improve quality of life. His coverage also includes developments that impact the cancer community, making him a valuable resource for those seeking the latest updates in the field.
For more in-depth articles, analysis, and coverage of the biotech sector, subscribe to STAT+ and unlock a world of exclusive content. Stay informed, stay ahead, and join us on the cutting edge of oncology and biotechnology.
